| Pharmacists’ perspectives of biosimilars: a systematic review N Mohd Sani, Z Aziz, R Panickar, A Kamarulzaman BioDrugs 36 (4), 489-508, 2022 | 13 | 2022 |
| An evaluation of Malaysian regulatory process for new active substances approved in 2017 using the OpERA methodology NM Sani, N McAuslane, SH Kasbon, R Ahmad, FAM Yusof, P Patel Therapeutic Innovation & Regulatory Science 54, 1215-1224, 2020 | 9 | 2020 |
| Cell and gene therapy products in Malaysia: a snapshot of the industry's current regulation preparedness EYX Loh, PS Goh, AMM Mannan, NM Sani, A Ab Ghani Cytotherapy 23 (12), 1108-1113, 2021 | 8 | 2021 |
| Biosimilars in Malaysia: regulatory framework, approved products, and adverse effects N Mohd Sani, Z Aziz, A Kamarulzaman Therapeutic Innovation & Regulatory Science 55, 490-502, 2021 | 7 | 2021 |
| Malaysian hospital pharmacists’ perspectives and their role in promoting biosimilar prescribing: a nationwide survey N Mohd Sani, Z Aziz, A Kamarulzaman BioDrugs 37 (1), 109-120, 2023 | 4 | 2023 |
| The use of technology in vaccine safety communication: A systematic review of randomised controlled trials R Panickar, Z Aziz, NM Sani, A Kamarulzaman Patient Education and Counseling 112, 107707, 2023 | 3 | 2023 |
| Use of biosimilars: a systematic review of published position statements and recommendations from health organisations and societies N Mohd Sani, Z Aziz, A Kamarulzaman BioDrugs 38 (3), 405-423, 2024 | 2 | 2024 |
| AB043. Biosimilar medicines: a cross-sectional study on hospital pharmacists’ perceived confidence and barriers to promote prescribing among clinicians in Malaysia NM Sani, Z Aziz, A Kamarulzaman Journal of Public Health and Emergency 5, 2021 | 1 | 2021 |
